Company news

Sanofi Sa (EURONEXT:SAN) news

Sanofi Sa news releases on 6ix. Latest, Apr 18, 2026: Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE…

Sanofi Sa (EURONEXT:SAN) news

Press releases — page 2

Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Sanofi: Information concerning the total number of voting rights and shares - March 2026

Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians

Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Press release: Availability of the Q1 2026 aide-mémoire

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases

Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Sanofi Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Sanofi announces leadership evolution in Specialty Care Business Unit

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi

Sanofi: Information concerning the total number of voting rights and shares – January 2026

Press Release: Sanofi completes the acquisition of Dynavax

Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026

Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Press Release: Myqorzo and Redemplo approved in China

Sanofi: Information concerning the total number of voting rights and shares - December 2025

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes

CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery

BrightInsight’s Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma